{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    44,
    45,
    46,
    47,
    48,
    49
  ],
  "modelUsed": "gemini-3-flash-preview",
  "interventions": {
    "studyInterventions": [
      {
        "id": "int_1",
        "name": "Canagliflozin",
        "type": {
          "id": "10c7030a-75c4-4981-a7bd-b3c1436890ae",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "role": {
          "id": "52e98842-7999-4fc0-9bc3-3ee4e13fe897",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus and diabetic nephropathy.",
        "productIds": [
          "prod_1"
        ],
        "administrationIds": [
          "admin_1"
        ]
      },
      {
        "id": "int_2",
        "name": "Placebo",
        "type": {
          "id": "404324ea-b9a2-4c66-8ceb-c811aa0a48af",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "role": {
          "id": "ea351fc5-593d-44f1-8778-8c9f33c02d65",
          "code": "C41132",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Placebo",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Matching placebo capsules for single-blind run-in and double-blind treatment phases.",
        "productIds": [
          "prod_2"
        ],
        "administrationIds": [
          "admin_2"
        ]
      },
      {
        "id": "int_3",
        "name": "ACEi or ARB",
        "type": {
          "id": "929c669d-80e2-40c7-a37a-1a8cfb8ab273",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "role": {
          "id": "b09383da-6896-4154-8e74-35c5101c0955",
          "code": "C54127",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Background Therapy",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker required for at least 4 weeks prior to randomization."
      },
      {
        "id": "int_4",
        "name": "Antihyperglycemic agents (AHA)",
        "type": {
          "id": "df6bd2a8-fc70-431a-9ebf-ed0cc1c01b0d",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a427b7a1-483e-4e88-a29a-d3cb4719e4bf",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Background AHA regimen adjusted to achieve glycemic goals using standard local guidelines."
      },
      {
        "id": "int_5",
        "name": "Mineralocorticoid receptor antagonist (MRA)",
        "type": {
          "id": "8ede237c-60c2-47f0-87cc-dbdfce04a2ad",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "0b71a625-4b6d-45a7-9d08-106bd81f19c1",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Restricted post-baseline use permitted if medically necessary; requires frequent monitoring of serum potassium."
      },
      {
        "id": "int_6",
        "name": "Direct renin inhibitor (DRI)",
        "type": {
          "id": "20bb2dbd-f0d1-4103-9b59-77814fbc5cd8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "ea671fd4-2a0d-4168-8f80-041de19853ed",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Subjects must be off therapy for at least 8 weeks prior to randomization."
      },
      {
        "id": "int_7",
        "name": "SGLT2 inhibitors",
        "type": {
          "id": "ce998473-9753-447b-ad73-c2d1653a031e",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "role": {
          "id": "a8f0fe00-f03d-41d0-9343-863b8db3eee8",
          "code": "C54126",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Concomitant Medication",
          "instanceType": "Code"
        },
        "instanceType": "StudyIntervention",
        "description": "Current use of other SGLT2 inhibitors is prohibited."
      }
    ],
    "administrableProducts": [
      {
        "id": "prod_1",
        "name": "Canagliflozin capsules",
        "administrableDoseForm": {
          "id": "50474a26-a6e9-452e-bdca-7e10e28be6fb",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "648ad91e-80a5-4577-8962-a95880c7c4c6",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "129721e3-eda2-4c6b-9d0f-c6b8daf47441",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "100 mg",
        "substanceIds": [
          "sub_1"
        ],
        "manufacturer": "Janssen Research & Development"
      },
      {
        "id": "prod_2",
        "name": "Placebo capsules",
        "administrableDoseForm": {
          "id": "0cfa7088-edf2-4619-8dd9-edba090f3d46",
          "code": "C25158",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Capsule",
          "standardCode": {
            "id": "6a5c372f-2acb-4b9a-8158-52483efc1cae",
            "code": "C25158",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Capsule",
            "instanceType": "Code"
          },
          "instanceType": "Code"
        },
        "productDesignation": {
          "id": "90fc42e7-ac3b-44ba-9bdc-3ea8e760213a",
          "code": "C54121",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Investigational Product",
          "instanceType": "Code"
        },
        "instanceType": "AdministrableProduct",
        "strength": "0 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "administrations": [
      {
        "id": "admin_1",
        "name": "Single-blind Run-in",
        "instanceType": "Administration",
        "dose": "1 capsule",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "2 weeks"
      },
      {
        "id": "admin_2",
        "name": "Double-blind Treatment",
        "instanceType": "Administration",
        "dose": "100 mg",
        "doseFrequency": "once daily",
        "route": {
          "code": "Oral",
          "codeSystem": "USDM",
          "decode": "Oral"
        },
        "duration": "Estimated 5 to 5.5 years (event-driven)"
      }
    ],
    "substances": [
      {
        "id": "sub_1",
        "name": "Canagliflozin",
        "instanceType": "Substance",
        "description": "JNJ-28431754; (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol"
      }
    ],
    "medicalDevices": [],
    "summary": {
      "interventionCount": 7,
      "productCount": 2,
      "deviceCount": 0
    }
  },
  "rawResponse": {
    "interventions": [
      {
        "name": "Canagliflozin",
        "role": "Investigational Product",
        "description": "Sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus and diabetic nephropathy."
      },
      {
        "name": "Placebo",
        "role": "Placebo",
        "description": "Matching placebo capsules for single-blind run-in and double-blind treatment phases."
      },
      {
        "name": "ACEi or ARB",
        "role": "Background Therapy",
        "description": "Maximum tolerated labeled daily dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker required for at least 4 weeks prior to randomization."
      },
      {
        "name": "Antihyperglycemic agents (AHA)",
        "role": "Concomitant Medication",
        "description": "Background AHA regimen adjusted to achieve glycemic goals using standard local guidelines."
      },
      {
        "name": "Mineralocorticoid receptor antagonist (MRA)",
        "role": "Concomitant Medication",
        "description": "Restricted post-baseline use permitted if medically necessary; requires frequent monitoring of serum potassium."
      },
      {
        "name": "Direct renin inhibitor (DRI)",
        "role": "Concomitant Medication",
        "description": "Subjects must be off therapy for at least 8 weeks prior to randomization."
      },
      {
        "name": "SGLT2 inhibitors",
        "role": "Concomitant Medication",
        "description": "Current use of other SGLT2 inhibitors is prohibited."
      }
    ],
    "products": [
      {
        "name": "Canagliflozin capsules",
        "doseForm": "Capsule",
        "strength": "100 mg",
        "manufacturer": "Janssen Research & Development"
      },
      {
        "name": "Placebo capsules",
        "doseForm": "Capsule",
        "strength": "0 mg",
        "manufacturer": "Janssen Research & Development"
      }
    ],
    "substances": [
      {
        "name": "Canagliflozin",
        "description": "JNJ-28431754; (1S)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol"
      }
    ],
    "administrations": [
      {
        "name": "Single-blind Run-in",
        "dose": "1 capsule",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "2 weeks"
      },
      {
        "name": "Double-blind Treatment",
        "dose": "100 mg",
        "frequency": "once daily",
        "route": "Oral",
        "duration": "Estimated 5 to 5.5 years (event-driven)"
      }
    ],
    "devices": []
  }
}